Replies to post #107 on Nkarta Inc (NKTX)

[jondoeuk]

Turns out the trial in solid tumours (ccRCC, mesothelioma, or osteosarcoma) is open. However, there are a number of differences, including design of the CAR (which has constitutive IL-15), ex vivo expansion, and they are using CB-derived NKs.

[jondoeuk]

Some more info. Pre-activation is IL-12/15/18 and expansion with uAPCs (engineered K562 feeder cells expressing mbIL-21 and 4-1BBL) plus IL-2, transduction with a retroviral vector, before another round of expansion. From two cord blood units, 250 doses have been manufactured with a (CAR) transduction efficiency of 60%. Six dose levels will be tested, with DL1 completed. Also, over 90 cryopreservation protocols were tested, with MDACC outperforming standard frozen.

[jondoeuk]

Updated